drug
TRAVOPROST
Marketedupdated 3mo agoby Sandoz Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 5Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 2 investigational indications.
all catalysts(11)
approval · 11
Sep 21, 2006
approval
TRAVATAN Z (TRAVOPROST) — FDA approval
TRAVOPROST
→
Aug 31, 2010
approval
TRAVATAN Z (TRAVOPROST) — FDA approval
TRAVOPROST
→
Sep 7, 2011
approval
TRAVATAN Z (TRAVOPROST) — FDA approval
TRAVOPROST
→
Mar 11, 2016
approval
TRAVATAN Z (TRAVOPROST) — FDA approval
TRAVOPROST
→
Sep 22, 2017
approval
TRAVATAN Z (TRAVOPROST) — FDA approval
TRAVOPROST
→
Apr 2, 2020
approval
TRAVATAN Z (TRAVOPROST) — FDA approval
TRAVOPROST
→
Dec 13, 2023
approval
$GKOS184.89-2.46%
IDOSE TR (TRAVOPROST) — FDA approval
TRAVOPROST
→
Oct 9, 2025
approval
TRAVATAN Z (TRAVOPROST) — FDA approval
TRAVOPROST
→
Dec 17, 2025
approval
TRAVOPROST — FDA approval
TRAVOPROST
→
Jan 27, 2026
approval
$GKOS184.89-2.46%
IDOSE TR (TRAVOPROST) — FDA approval
TRAVOPROST
→
Jan 27, 2026
approval
$GKOS184.89-2.46%
IDOSE TR (TRAVOPROST) — FDA approval
TRAVOPROST
→
Trials studying TRAVOPROST
- phase4Travoprost Intraocular Implant + iStent Infinite
- phase3Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
- phase3Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
- —Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg
- phase4Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone
- phase4Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma
- phase2A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)
- phase3Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%
Patent cliff
source: FDA Orange Bookfirst barrier falls
Dec 13, 2026
114 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (11)
- Feb 14, 2031compositionUS 122015554.5y
- Oct 17, 2030formulationUS 102068134.2y
- Oct 17, 2030formulationUS 114263064.2y
- Jun 18, 2030compositionUS 122015573.8y
- Oct 13, 2029formulationUS 82682993.1y
- Oct 10, 2029formulationUS 81785823.1y
- Oct 10, 2029formulationUS 87227353.1y
- May 19, 2029formulationUS 87541232.7y
- Mar 13, 2029formulationUS 91445612.6y
- Sep 20, 2027formulationUS 83236301.1y
- Sep 20, 2027formulationUS 83889411.1y
FDA exclusivities (1)
- Dec 13, 2026NPNP114d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 36m ago
Found something off?
comments(0)
5-min edit window · permanent after that